Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Robotic versus laparoscopic urological surgery: incidence of reoperation and complications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A case of xanthogranulomatous inflammation of the urethra treatment with a steroid-based non-surgical approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Abstract Objective. The aim of this study was to evaluate overall survival (OS) after treatment of metastatic renal cell carcinoma (mRCC) following the introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors. Material and methods. One-hundred and forty-three consecutive mRCC patients were given immunotherapy (n = 59), TKIs (n = 49) or sequential therapy (IMM→TKI group; n = 35). The TKI group included patients with higher age (p < 0.001), worse performance status (p = 0.005) and higher risk profile (p < 0.001) than the other two treatment groups. Number of metastases and sites and tumour histology did not differ between groups. Results. First line immunotherapy gave a median OS of 16.3 months and first line TKIs 10.9 months (p = 0.003). Survival longer than 5 years was limited to immunotherapy. Sarcomatoid component, metastatic sites, papillary histology, stage, performance status and white cell blood count were related to poor OS. Using multivariate analyses to adjust for risk predictors the difference in OS disappeared. Median OS before and after introduction of TKIs was 16 months and 14 months, respectively (p = 0.189). Memorial Sloan Kettering Cancer Center (MSKCC) risk groups were related to OS (p < 0.001). Heng's prognostic criteria appeared slightly more predictive than MSKCC (p = 0.12). Metastasectomy (n = 42) may improve OS [surgery: median OS 18.8 months, 95% confidence interval (CI) 12.3-48.5; no surgery: median OS 15 months, 95% CI 10.4-16.5; p = 0.07]. Conclusions. MSKCC and Heng's prognostic algorithms were valid for prognostication and can be used for individual planning of treatment and follow-up. Surgical removal of metastases may improve OS.

OriginalsprogEngelsk
TidsskriftScandinavian Journal of Urology
Vol/bind48
Udgave nummer4
Sider (fra-til)379-86
ISSN0036-5599
DOI
StatusUdgivet - 12 feb. 2014

ID: 44261384